



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#13

In re application of:

ATKINSON, et al.

Serial. No. 09/554,941

Filed: May 22, 2000

For: DNA ENCODING PROTEINASE
INHIBITOR FUSION PROTEINS
(New Title)

Art Unit: 1638

Examiner: KUBELIK, ANNE

Atty Docket: S-30287A

Confirmation No.: 5118

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. Copies of the listed items are enclosed herewith. Further, in accordance with 37 C.F.R. § 1.97(c)(2), since the instant Information Disclosure Statement is being filed prior to the mailing of any final action, this submission is accompanied by the appropriate fee set forth in § 1.17(p). The Examiner is respectfully requested to fully consider the items in relation to this application and to indicate that each reference was considered by returning a copy of the initialed PTO 1449 forms.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute any of the listed documents as prior art during examination. Further, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the

claims of the present application. Further, the submission of the Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Commissioner is authorized to charge \$180.00 for payment of this submission pursuant to 37 C.F.R. § 1.17(p), to Applicant's credit card. A Credit Card Payment Form is attached hereto. The Commissioner is authorized to charge any additional fees under 37 C.F.R. §1.17 that may be required, to Deposit Account No. 50-1744 in the name of Syngenta.

Respectfully submitted,



Marcia R. Morton
Attorney for Applicants
Registration No. 46,942

Syngenta Biotechnology, Inc.
P. O. Box 12257
Research Triangle Park, NC 27709-2257

Date: October 9, 2002